Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03071770
Recruitment Status : Completed
First Posted : March 7, 2017
Last Update Posted : January 11, 2018
Information provided by (Responsible Party):
Agios Pharmaceuticals, Inc.

Brief Summary:
The purpose of this Phase I, single-dose, open-label trial is to evaluate the pharmacokinetics and safety of ivosidenib (AG-120) in healthy, adult male Japanese and Caucasian subjects. The study plans to evaluate 3 cohorts of a single oral dose of ivosidenib (AG-120) in Japanese and Caucasian subjects. Pharmacokinetic sampling will take place serially through-out the duration of subject participation.

Condition or disease Intervention/treatment Phase
Healthy Drug: ivosidenib (AG-120) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Single-Dose, Open-Label Trial to Evaluate the Pharmacokinetics and Safety of AG-120 in Healthy Male Japanese Subjects Relative to Healthy Male Caucasian Subjects
Actual Study Start Date : March 31, 2017
Actual Primary Completion Date : May 9, 2017
Actual Study Completion Date : September 6, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Ivosidenib

Arm Intervention/treatment
Experimental: ivosidenib (AG-120) Drug: ivosidenib (AG-120)
A single-dose of ivosidenib (AG-120) administered in healthy Japanese and Caucasian subjects

Primary Outcome Measures :
  1. AUC [ Time Frame: Pharmacokinetic sampling for ivosidenib (AG-120) will be taken for 504 hours (21 days) after single dose ]
    AG-120 Area Under the Curve

  2. Cmax [ Time Frame: Pharmacokinetic sampling for ivosidenib (AG-120) will be taken for 504 hours (21 days) after single dose ]
    AG-120 Maximum Plasma Concentration

Secondary Outcome Measures :
  1. Incidence of Adverse Events [ Time Frame: 28 days after single-dose ivosidenib (AG-120) ]
    Assessment of adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Applicable to Japanese Subjects Only: Japanese subjects must have been born in Japan, have both parents and grandparents of Japanese origin, and not have lived outside of Japan for more than 5 years.
  • Applicable to Caucasian Subjects Only: Non-Japanese subjects must be Caucasian (ie, White) but may be of any ethnicity.
  • Healthy male subjects between 18 and 55 years of age (inclusive).
  • Provision of voluntary, written informed consent.
  • Capable of adhering to trial restrictions and examination schedules, in the opinion of the Investigator.
  • Must be able to communicate with the Investigator.
  • Must be in good health as determined by the Investigator according to past medical history, physical examination, vital signs, clinical laboratory test results, and ECGs.
  • Must have a body mass index (BMI) between 18 and 29 kg/m2 (inclusive), and body weight between 50-120kg.
  • Clinical laboratory test results (serum chemistry, hematology, and urinalysis) must be within normal limits or considered by the Investigator to be not clinically significant after confirmation with the Agios Medical Monitor.
  • Vital signs (systolic and diastolic blood pressure, pulse rate, and oral body temperature) will be assessed in the supine position after the subject has rested for at least 5 minutes. Subject must be afebrile with vital signs within the following ranges at screening, Day -1 and pre dose: Systolic blood pressure: 90 to 140 mmHg; Diastolic blood pressure: 50 to 90 mmHg; Pulse rate: 40 to 110 bpm
  • Must have a normal or clinically acceptable 12-lead ECG no later than Day -1. Subjects must have a pre-dose QT interval corrected for heart rate using Fridericia's formula (QTcF) value or average of 3 values, ≤450 msec. An ECG may be repeated once to determine subject eligibility after confirmation with the Agios Medical Monitor.
  • Subjects (with or without vasectomy) must agree to abstain from sexual intercourse or agree to the use of highly effective contraceptive methods (at screening and throughout the course of the trial) and should avoid fathering a child during the course of the trial and for 90 days following the dose of the IMP. Subjects must refrain from sperm donations for the entire duration of the trial and for 90 days following the dose of AG 120.

Exclusion Criteria:

  • Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from providing informed consent or participating in the trial in the opinion of the Investigator.
  • Any condition, including the presence of laboratory abnormalities, which places the subject at an unacceptable risk if he were to participate in the trial.
  • Recent history (within 3 years prior to dosing) of any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, or other major disorder.
  • Use of any prescribed systemic or topical medication within 30 days or 5 terminal half-lives, whichever is longer, of IMP administration.
  • Exposure to an investigational drug within 30 days prior to IMP administration or 5 half lives of that investigational drug, if known (whichever is longer).
  • Use of any non-prescribed systemic or topical medication (including vitamin/mineral supplements, and herbal medicines, eg, St. John's Wort) within 7 days of IMP administration.
  • Any surgical or medical condition that could affect drug absorption, distribution, metabolism, or excretion (eg, gastrectomy and cholecystectomy)
  • Subjects who plan to have any elective or medical procedures during the conduct of the trial (eg, dental procedure).
  • History of clinically significant multiple drug allergies (ie, 2 or more).
  • Any clinically significant allergic disease.
  • History of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual [DSM]) within 2 years prior to IMP administration, or positive drug screen test due to illicit drugs at any time prior to IMP administration during the screening period.
  • History of alcohol abuse within 2 years prior to IMP administration, or positive alcohol screen at any time prior to IMP administration during the screening period.
  • History of smoking within 3 months prior to IMP administration, or positive urine cotinine screen at any time prior to IMP administration during the screening period.
  • Known to have human immunodeficiency virus (HIV), hepatitis, or known to be a carrier of the hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV Ab), or have positive results at screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03071770

Layout table for location information
United States, California
West Coast Clinical Trial (WCCT)
Cypress, California, United States, 90630
Sponsors and Collaborators
Agios Pharmaceuticals, Inc.
Layout table for investigator information
Study Chair: Medical Affairs Agios Pharmaceuticals, Inc Agios Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Agios Pharmaceuticals, Inc. Identifier: NCT03071770    
Other Study ID Numbers: AG120-C-006
First Posted: March 7, 2017    Key Record Dates
Last Update Posted: January 11, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Agios Pharmaceuticals, Inc.:
Healthy Volunteers
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action